PWAR5 Expression Vector for HCV Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infections are limited by high costs, severe side effects, and vulnerability to viral variants, necessitating the development of novel therapeutic agents that can effectively inhibit HCV proliferation at an affordable price.
Innovation Solution
A pharmaceutical composition containing a stimulant for PWAR5 expression is developed as an active ingredient to prevent or treat infectious diseases caused by HCV. This composition includes polynucleotides, complementary polynucleotides, or vectors capable of expressing PWAR5, which is overexpressed in cells to inhibit HCV proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct antiviral agents (DAAs) are used to treat HCV infection, then treatment success rate increases to over 90%, but the cost becomes very expensive creating a barrier to practical treatment
Solution Approach 1:
The patent uses a short hairpin RNA (shRNA) expression vector that can be administered as a single dose or limited courses to achieve sustained HCV suppression. The shRNA molecules are designed to be transient but effective, reducing the need for long-term expensive DAA therapy while maintaining high treatment success rates.
Solution Approach 2:
The patent changes the therapeutic approach from small molecule drugs (DAAs) to nucleic acid-based therapy (shRNA). This parameter change in the mode of action allows for a different cost structure while achieving comparable or superior efficacy against HCV, including resistant variants.
2Reliability
If DAAs are used to treat HCV infection, then viral proliferation is inhibited, but the therapeutic agents become vulnerable to viral variants due to frequent HCV mutation
Solution Approach 1:
The shRNA expression vector targets multiple regions of the HCV genome simultaneously through different hairpin structures. This segmentation of the viral genome into multiple targets makes it difficult for the virus to develop resistance through single point mutations, as the virus would need to mutate multiple sites simultaneously to escape all shRNA targets.
Solution Approach 2:
The shRNA expression system is designed to be universally effective against different HCV genotypes and variants. The multiple hairpin structures target conserved regions of the viral genome, providing broad-spectrum activity that is not easily bypassed by viral mutation, thus achieving multi-functionality against diverse viral strains.
3Ease of operation
If interferon monotherapy is used to treat HCV infection, then treatment can be administered, but the treatment success rate remains very low at only 10%
Solution Approach 1:
The patent combines multiple functional elements within a single shRNA expression vector: multiple hairpin structures targeting different viral sequences, regulatory elements for controlled expression, and selection markers. This composite structure integrates the advantages of multiple therapeutic approaches into one system, achieving high efficacy that overcomes the limitations of interferon monotherapy.
Data Source
AI summary
The present invention relates to a pharmaceutical composition and the like containing a stimulant for PWAR5 expression as an active ingredient for preventing or treating infectious diseases due to hepatitis C virus, the present invention allowing the PWAR5 level to be sustained at a high level inside the cell to effectively inhibit proliferation of HCV.